Clinical Data And TrialsThe readout will be a significant event for the stock, and analysts are bullish on CDTX based on the Ph2a clinical data and the recently updated Ph2b statistical analysis plan.
Commercial PotentialCDTX’s technology not only promises to save lives, but it also promises to save billions of dollars in annual healthcare costs from flu.
Market PerformanceAnalyst reiterates a Market Outperform rating for Cidara Therapeutics, suggesting confidence in the company's future performance.